TNFRSF17 and neoplasm: They have two binding sites, one end binds to tumor cell surface antigens, currently involved in B cell maturation antigen(BCMA), CD38, CD19, G protein-coupled receptor class C group 5 member D(GPRC5D) and Fc receptor-like 5(FCRL5), and the other end binds to molecules on immune effector cells, such as CD3 on T cell and CD16 on NK cell (31).